Isbn: 9781957588445 - biotech in the balance: saving a strategic industry in an age of distrust (21 risultati)

hardcover. Condizione: Very Good. Connecting readers with great books since 1972! Used books may not include companion materials, and may have some shelf wear or limited writing. We ship orders daily and Customer Service is our top priority.

Hardcover. Condizione: As New. No Jacket. Pages are clean and are not marred by notes or folds of any kind. ~ ThriftBooks: Read More, Spend Less.

Condizione: As New. Unread copy in mint condition.

Condizione: New. Brand New.

Hardback or Cased Book. Condizione: New. Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust. Book.

Hardback. Condizione: New.

Condizione: New.

Hardcover. Condizione: new. Hardcover. "The choice to invest in vaccines rather than in weapons; in treatments for rare diseases rather than in speculative consumer products; in long-term infrastructure rather than in short-term optics--these are not technical decisions. They are moral decisions . . ." Biotech in the Balance by Dr. Jeremy M. Levin shows why the next lifesaving medicines may not arrive on time, and what we can do about that in a period of political change. This is not a technical book. It is a bedside-to-boardroom story, told from inside the system, with a clear map of what has to change so that medicines keep arriving when people need them. When funding for research and development is politicized, trust in science erodes and the foundations of biotechnology weaken. When science is treated as a partisan symbol rather than a shared foundation for health, patients and families bear the consequences. Dr. Levin's career began as a scientist studying the structure of DNA, and then as a physician in university hospitals in London, Cape Town, and Geneva. As a doctor, he saw the difference between patients saved by medicines that arrived just in time, and those who were not so fortunate. That experience led to a simple conviction: drug discovery and development is not an abstract business. It is a living coalition of scientists, governments, businesses, and--above all--patients. For patients and their families, profitability and internal strategy are not the point. What matters is whether a therapy works, how quickly results can be seen, and how benefits are weighed against risks--including the risk of doing nothing. Throughout the book, Dr. Levin keeps patients at the center of the discussion--politics, markets, supply chains, and governance--and shows how each of these forces can accelerate or delay medical progress. Written from the perspective of a scientist and physician, Biotech in the Balance argues for a resilient, globally competitive biotechnology industry built to serve patients and earn lasting public trust. It offers a call to action for preserving biotechnology as a strategic asset--and a practical framework for leaders who want to strengthen the system rather than merely defend it. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. …

Hardback. Condizione: New.

HRD. Condizione: New. New Book. Shipped from UK. Established seller since 2000.

Hardcover. Condizione: Brand New. 192 pages. 8.00x5.00x8.00 inches. In Stock.

Hardcover. Condizione: Brand New. 192 pages. 8.00x5.00x8.00 inches. In Stock.

hardcover. Condizione: New. Special order direct from the distributor.

Hardback. Condizione: New. New copy - Usually dispatched within 4 working days.

Condizione: New. 2026. hardcover. . . . . . Books ship from the US and Ireland.

Condizione: New. 2026. hardcover. . . . . .

Buch. Condizione: Neu. Neuware - "The choice to invest in vaccines rather than in weapons; in treatments for rare diseases rather than in speculative consumer products; in long-term infrastructure rather than in short-term opticsthese are not technical decisions. They are moral decisions . . ."Biotech in the Balance by Dr. Jeremy M. Levin shows why the next lifesaving medicines may not arrive on time, and what we can do about that in a period of political change. This is not a technical book. It is a bedside-to-boardroom story, told from inside the system, with a clear map of what has to change so that medicines keep arriving when people need them. When funding for research and development is politicized, trust in science erodes and the foundations of biotechnology weaken. When science is treated as a partisan symbol rather than a shared foundation for health, patients and families bear the consequences. Dr. Levin's career began as a scientist studying the structure of DNA, and then as a physician in university hospitals in London, Cape Town, and Geneva. As a doctor, he saw the difference between patients saved by medicines that arrived just in time, and those who were not so fortunate. That experience led to a simple conviction: drug discovery and development is not an abstract business. It is a living coalition of scientists, governments, businesses, andabove allpatients. For patients and their families, profitability and internal strategy are not the point. What matters is whether a therapy works, how quickly results can be seen, and how benefits are weighed against risksincluding the risk of doing nothing. Throughout the book, Dr. Levin keeps patients at the center of the discussionpolitics, markets, supply chains, and governanceand shows how each of these forces can accelerate or delay medical progress. Written from the perspective of a scientist and physician, Biotech in the Balance argues for a resilient, globally competitive biotechnology industry built to serve patients and earn lasting public trust. It offers a call to action for preserving biotechnology as a strategic assetand a practical framework for leaders who want to strengthen the system rather than merely defend it. …

Hardcover. Condizione: new. Hardcover. "The choice to invest in vaccines rather than in weapons; in treatments for rare diseases rather than in speculative consumer products; in long-term infrastructure rather than in short-term optics--these are not technical decisions. They are moral decisions . . ." Biotech in the Balance by Dr. Jeremy M. Levin shows why the next lifesaving medicines may not arrive on time, and what we can do about that in a period of political change. This is not a technical book. It is a bedside-to-boardroom story, told from inside the system, with a clear map of what has to change so that medicines keep arriving when people need them. When funding for research and development is politicized, trust in science erodes and the foundations of biotechnology weaken. When science is treated as a partisan symbol rather than a shared foundation for health, patients and families bear the consequences. Dr. Levin's career began as a scientist studying the structure of DNA, and then as a physician in university hospitals in London, Cape Town, and Geneva. As a doctor, he saw the difference between patients saved by medicines that arrived just in time, and those who were not so fortunate. That experience led to a simple conviction: drug discovery and development is not an abstract business. It is a living coalition of scientists, governments, businesses, and--above all--patients. For patients and their families, profitability and internal strategy are not the point. What matters is whether a therapy works, how quickly results can be seen, and how benefits are weighed against risks--including the risk of doing nothing. Throughout the book, Dr. Levin keeps patients at the center of the discussion--politics, markets, supply chains, and governance--and shows how each of these forces can accelerate or delay medical progress. Written from the perspective of a scientist and physician, Biotech in the Balance argues for a resilient, globally competitive biotechnology industry built to serve patients and earn lasting public trust. It offers a call to action for preserving biotechnology as a strategic asset--and a practical framework for leaders who want to strengthen the system rather than merely defend it. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. …

Hardback. Condizione: New.

Hardcover. Condizione: new. Hardcover. "The choice to invest in vaccines rather than in weapons; in treatments for rare diseases rather than in speculative consumer products; in long-term infrastructure rather than in short-term optics--these are not technical decisions. They are moral decisions . . ." Biotech in the Balance by Dr. Jeremy M. Levin shows why the next lifesaving medicines may not arrive on time, and what we can do about that in a period of political change. This is not a technical book. It is a bedside-to-boardroom story, told from inside the system, with a clear map of what has to change so that medicines keep arriving when people need them. When funding for research and development is politicized, trust in science erodes and the foundations of biotechnology weaken. When science is treated as a partisan symbol rather than a shared foundation for health, patients and families bear the consequences. Dr. Levin's career began as a scientist studying the structure of DNA, and then as a physician in university hospitals in London, Cape Town, and Geneva. As a doctor, he saw the difference between patients saved by medicines that arrived just in time, and those who were not so fortunate. That experience led to a simple conviction: drug discovery and development is not an abstract business. It is a living coalition of scientists, governments, businesses, and--above all--patients. For patients and their families, profitability and internal strategy are not the point. What matters is whether a therapy works, how quickly results can be seen, and how benefits are weighed against risks--including the risk of doing nothing. Throughout the book, Dr. Levin keeps patients at the center of the discussion--politics, markets, supply chains, and governance--and shows how each of these forces can accelerate or delay medical progress. Written from the perspective of a scientist and physician, Biotech in the Balance argues for a resilient, globally competitive biotechnology industry built to serve patients and earn lasting public trust. It offers a call to action for preserving biotechnology as a strategic asset--and a practical framework for leaders who want to strengthen the system rather than merely defend it. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. …

Hardback. Condizione: New.